Skip to main content
NewslettersWatchlist

Intellia Thera CS(NTLA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low25.81
Day High26.55
Open:26.05
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Motley Fool
2 Stocks Down 30% to Buy Right Now
Motley Fool
Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week.
Motley Fool
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
Motley Fool
Better Cathie Wood Stock: Moderna vs. Intellia
Motley Fool
Is Intellia Therapeutics Stock a Buy Now?
Motley Fool
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Motley Fool
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
Motley Fool
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Motley Fool
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
Motley Fool
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
Motley Fool
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
Motley Fool
Is It Too Late to Buy Intellia Therapeutics Stock?
Motley Fool
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Motley Fool
The Top Healthcare Stocks to Buy With $100
Motley Fool
Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics
Motley Fool
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
Motley Fool
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
Motley Fool
5 Beaten-Down Stocks That Could Soar in 2024
Motley Fool
Could Intellia Therapeutics Become the Next CRISPR Therapeutics?
Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Motley Fool
2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market
Motley Fool
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
Motley Fool
Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy?
Motley Fool
3 Stocks Cathie Wood Is Buying That Should Be on Your List Too
Motley Fool
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time
Motley Fool
2 Healthcare Stocks Near 52-Week Highs Still Worth Buying
Motley Fool
2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years
Motley Fool
2 Brilliant Growth Stocks to Buy and Hold Forever

Profile

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the therapy and ex vivo programs that use CRISPR to create the therapy by using engineered human cells.'

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.